Here you'll find the latest press releases on VIB research and other important news.
Ghent-based company Protealis, a new spin-off from VIB and ILVO, is making its debut today in the plant breeding industry. Inspired by the mission to grow more sustainable plant-based proteins locally, Protealis aims to harvest the full potential of legume crops.
Human glioblastoma tumors are aggressive hard-to-treat brain cancers that have a high unmet need for new treatment options. A team of researchers led by Prof. Kiavash Movahedi and Prof. Jo Van Ginderachter (VIB-VUB), in collaboration with colleagues from VIB, VUB, and KU Leuven, have mapped the immune landscape in these glioblastoma tumors.
VIB and the biopharmaceutical company Complix today announce the publication of a joint study in the journal Science Advances. In this work the scientific teams could design an Alphabody™ that efficiently penetrates the cell membrane, disrupts an intracellular protein-protein interface, and carries an in vivo serum half-life extension technology.
Biotalys, an AgTech company focused on addressing food protection challenges to enable a more sustainable and safe food supply, announced it has submitted the registration dossier for the active substance of its first protein-based biocontrol product, Evoca™, for EU approval.
Augustine Therapeutics, a VIB spin off that focuses on the development of novel innovative therapies for rare peripheral neuropathies and neurogenerative disorders, has received EUR 1.2 million in funding from the Flanders Agency for Innovation & Entrepreneurship (VLAIO).
Spring is in the air. And how do we enjoy the awakening of nature these days… A passion VIB's plant scientists share day in day out. Their dedication to plant science helps us to tackle some crucial challenges our planet faces today. We gladly present some of VIB's plant projects.
The reinforcement of Augustine Therapeutics’ boards is another important step in strengthening the company to further the development of new medicines treating multiple neurodegenerative diseases with high unmet need.
With the virtual conference 'Plant Science for Climate Emergency', they seek to unite researchers and stakeholders from across scientific domains to lead the way in tackling the biggest challenge of our time.
Augustine Therapeutics, a biotech company focused on the development of innovative medicines for rare peripheral neuropathies and neurodegenerative diseases, announces the appointment of Dr. Sylvain Celanire, PhD as its Chief Executive Officer and the opening of drug discovery laboratories at the Leuven Bio-Incubator in Belgium.
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising a total of EUR 42 million / US$50 million.
Een studie gecoördineerd door het UZ Gent en gefinancierd door het KCE Trials Programme van het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) toont aan dat de reumageneesmiddelen tocilizumab, siltuximab en anakinra geen impact hebben bij de behandeling van Belgische gehospitaliseerde COVID-19-patiënten.
A team of researchers led by Philip Van Damme and Ludo Van Den Bosch (VIB-KU Leuven Center for Brain & Disease Research) used stem cells derived from ALS-patients to study the role of TDP-43 mutations in the disease process.
Orionis Biosciences and The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division announced the launch of Project Helios, a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions.
The Laboratory of Cellular Metabolism and Metabolic Regulation headed by Prof. Sarah-Maria Fendt (VIB-KU Leuven Center for Cancer Biology), shows how the livers of mice on a high-fat diet used glucose in a way similar to aggressive cancer cells.
The COVID-19 antibody developed by the VIB-UGent teams of Xavier Saelens and Nico Callewaert has completed the drug development trajectory. Antibody therapeutics will be vital to treat people not yet vaccinated and immunocompromised people.